Gamcemetinib

• CAT Number: I044392
• CAS Number: 1887069-10-4
• Molecular Formula: C22H20ClN5O3S
• Molecular Weight: 469.94
• Purity: ≥95%
• Synonyms: (15R)-5-[2-chloro-5-(ethoxymethyl)pyrimidin-4-yl]oxy-15-methyl-11-thia-6,14,17-triazatetracyclo[8.8.0.02,7.012,18]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one
• InChI: InChI=1S/C22H20ClN5O3S/c1-3-30-10-12-9-25-22(23)28-21(12)31-16-7-4-13-14(27-16)5-6-15-17(13)18-19(32-15)20(29)26-11(2)8-24-18/h4-7,9,11,24H,3,8,10H2,1-2H3,(H,26,29)/t11-/m1/s1
• InChIKey: PYOQIOLRFIRRSO-LLVKDONJSA-N
• SMILES: CCOCC1=CN=C(N=C1OC2=NC3=C(C=C2)C4=C(C=C3)SC5=C4NC[C@H](NC5=O)C)Cl

Gamcemetinib（Cat No.:I044392）is an investigational small-molecule inhibitor targeting multiple tyrosine kinases, including MET and VEGFR2, which are implicated in tumor growth, angiogenesis, and metastasis. By blocking these signaling pathways, Gamcemetinib disrupts cancer cell proliferation and the vascular support essential for tumor survival. It demonstrates potent antitumor activity in preclinical models of solid tumors, particularly those with MET overexpression or amplification. With favorable pharmacokinetics and selectivity, Gamcemetinib is being explored as a targeted therapy in oncology, offering potential benefits in treating cancers resistant to conventional chemotherapies or monotherapies.